Share

Reduced Time in Hypoglycemia Demonstrated in Recent Insulin Pump Trial

Positive results were announced this week from the study of a new insulin pump with a predictive low glucose suspend (PLGS) feature. Data showed that the system achieved the primary outcome of reducing time spent in hypoglycemia compared to sensor-augmented pump therapy alone. The company developing the device, Tandem Diabetes Care, is marketing its new...
Share

FDA Approves Semaglutide Injection For the Treatment of Adults with Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) approved semaglutidea once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The drug, produced by Novo Nordisk and marketed as OZEMPIC®, is administered once weekly, on the same day each week, and can be taken...
Share

Study Shows People with Type 2 Diabetes Benefit from Continuous Glucose Monitoring

The results show that continuous glucose monitoring is an effective diabetes management tool that could benefit millions of people with type 2 diabetes on insulin therapy People with type 2 diabetes on a multiple daily injection (MDI) insulin therapy benefit from the use of continuous glucose monitoring (CGM), according to a study recently published in...
Share

Researchers Studying Novel Gestational Diabetes Screening Alternative

Researchers at Brigham and Women’s Hospital (BWH) recently published a study demonstrating the potential clinical utility of glycated CD59 (GCD59) as a novel biomarker for the screening and diagnosis of gestational diabetes mellitus (GDM). The data from this study showed that a single blood test that measures plasma GCD59 at week 24-28 of gestation identified...